Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers

Journal of Artificial Organs

Volumn 15, Issue 2, 2012, Pages 193-199

  Yamada, Naoto ^a,b   Uchinuma, Eiju ^b   Kuroyanagi, Yoshimitsu ^c  

^a Yokohama Minami Kyosai Hospital   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Allogeneic cultured dermal substitutes; Basic fibroblast growth factor; Fibroblast; Skin ulcer

Indexed keywords

ATELOCOLLAGEN; FIBROBLAST GROWTH FACTOR 2; HYALURONIC ACID;

ADULT; AGED; ALLOGENEIC CULTURED DERMAL SUBSTITUTE; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CRYOPRESERVATION; DRUG TREATMENT FAILURE; EPITHELIZATION; FEMALE; FIBROBLAST CULTURE; GRANULATION TISSUE; HUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; SKIN REGENERATION; SKIN ULCER; TISSUE REGENERATION; TREATMENT DURATION; ULCER HEALING; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; SKIN TRANSPLANTATION; SKIN ULCER; SKIN, ARTIFICIAL; TISSUE ENGINEERING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84864699011     PISSN: 14347229     EISSN: 16190904     Source Type: Journal    
DOI: 10.1007/s10047-011-0618-0     Document Type: Article

References (32)

1. Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelocollagen combined with fibroblasts: Fundamental evaluation. J Biomater Sci Polym Ed. 2003;14:625-41. (Pubitemid 36926689)
2. Kubo K, Kuroyanagi Y. Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: Evaluation in an animal test. J Artif Organs. 2003;6:64-70. (Pubitemid 36554089)
3. Kubo K, Kuroyanagi Y. Characterization of cultured dermal substitute composed of spongy matrix of hyaluronic acid and collagen combined with fibroblasts. J Artif Organs. 2003;6: 138-44. (Pubitemid 36829956)
4. Kubo K, Kuroyanagi Y. Effects of vascular endothelial growth factor released from cultured dermal substitute on proliferation of vascular endothelial cells in vitro. J Artif Organs. 2003;6:267-72. (Pubitemid 38031319)
5. Kuroyanagi Y, Kubo K, Matsui H, Kim HJ, Numari S, Mabuchi Y, Kagawa S. Establishment of banking system for allogeneic cultured dermal substitute. Artif Organs. 2004;28:13-21. (Pubitemid 38234239)
6. Kubo K, Kuroyanagi Y. Development of a cultured dermal substitute composed of a spongy matrix of hyaluronic acid and atelocollagen combined with fibroblasts: Cryopreservation. Artif Organs. 2004;28:182-8. (Pubitemid 38339001)
7. Kubo K, Kuroyanagi Y. The possibility of long-term cryopreservation of cultured dermal substitute. Artif Organs. 2005;29: 800-5. (Pubitemid 43934119)
8. Kubo K, Kuroyanagi Y. A study of cytokines released form fibroblasts in culture dermal substitute. Artif Organs. 2005;29: 845-9. (Pubitemid 43934126)
9. Hashimoto A, Kuroyanagi Y. Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-b, and IL-8. J Artif Organs. 2008;11:225-31.
10. Kashiwa N, Ito O, Ueda T, Kubo K, Matsui H, Kuroyanagi Y. Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured dermal substitute. Artif Organs. 2004;28:444-50. (Pubitemid 38680157)
11. Ohtani T, Okamoto K, Kaminaka C, Kishi T, Sakurane M, Yamamoto Y, Ueda K, Kubo K, Kuroyanagi Y, Furukawa F. Digital gangrene associated with idiopathic hypereosinophilia: Treatment with allogeneic cultured dermal substitute. Eur J Dermatol. 2004;14:168-71. (Pubitemid 38738457)
12. Moroi Y, Fujita S, Fukagawa S, Mashino T, Goto T, Masuda T, Urabe K, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y, Furue M. Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection. Eur J Dermatol. 2004;14:172-6. (Pubitemid 38738458)
13. Hasegawa T, Suga Y, Mizoguchi M, Ikeda S, Ogawa H, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2004;50:803-4. (Pubitemid 38580573)
14. Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Mizuno Y, Ogawa H, Kubo K, Kuroyanagi Y. An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: Three case reports. J Dermatol. 2005;32:715-20. (Pubitemid 41442071)
15. Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Mizuno Y, Haruna K, Ikeda S, Kuroyanagi Y, Ogawa H. Intractable venous leg ulcer treated successfully with allogeneic cultured dermal substitute. Scand J Plast Reconstr Surg Hand Surg. 2007;41:326-8.
16. Yonezawa M, Tanizaki H, Inoguchi N, Ishida M, Katoh M, Tachibana T, Miyachi Y, Kubo K, Kuroyanagi Y. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers. Int J Dermatol. 2007;46:36-42. (Pubitemid 46029722)
17. Nishimoto J, Amoh Y, Tanabe K, Niiyama N, Katsuoka K, Kuroyanagi Y. Intractable leg ulcers associated with antiphospholipid syndrome with stasis dermatitis: Treatment with allogeneic cultured dermal substitute. Eur J Dermatol. 2007; 17(4):350-1. (Pubitemid 47051565)
18. Yamada N, Uchinuma E, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of lower leg. J Artif Organs. 2008;11:100-3. (Pubitemid 351950606)
19. Yamada N, Uchinuma E, Matsumoto Y, Kuroyanagi Y. Comparative evaluation of re-epithelialization promoted by fresh or cryopreserved cultured dermal substitute. J Artif Organs. 2008; 11:221-4.
20. Ohara N, Mihara S, Nihara H, Akimoto N, Madokoro N, Kawai M, Noda H, Hide M, Matsumoto Y, Kuroyanagi Y. A case of lower-extremity deep burn wounds with periosteal necrosis successfully treated by use of allogeneic cultured dermal substitute. J Artif Organs. 2010;13:101-5.
21. Clark RA. Continuing medical education. Cutaneous tissue repair: Basic biologic considerations I. J Am Acad Dermatol. 1985;13:701-25. (Pubitemid 16245140)
22. Fu X, Shen Z, Chen Y. Basic fibroblast growth factor (bFGF) and wound healing: A multi-centers controlled clinical trial in 1024 cases. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1998;12:209-11.
23. Yamanaka K, Inaba T, Nomura E, Hurwitz D, Jones DA, Hakamada A, Isoda K, Kupper TS, Mizutani H. Basic fibroblasts growth factor treatment for skin ulceration in scleroderma. Cutis. 2005;76:373-6. (Pubitemid 43104480)
24. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58-65.
25. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, Andia I. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84:415-21.
26. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M. Clinical efficacy of basic growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19:461-8.
27. Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care. 2009;18:516-9.
28. Yan X, Chen B, Lin Y, Li Y, Xiao Z, Hou X, Tan Q, Dai J. Acceleration of diabetic wound healing by collagen-binding vascular endothelial growth factor in diabetic rat model. Diabetes Res Clin Pract. 2010;90:66-72.
29. Culp LA, Murray BA, Rollins BJ. Fibronectin and proteoglycans as determinants of cell-substratum adhesion. J Supramol Struct. 1979;11:401-27. (Pubitemid 10069150)
30. Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials. 1993;14:1154-60. (Pubitemid 24061573)
31. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagenderived peptides. Proc Natl Acad Sci USA. 1978;75:871-5. (Pubitemid 8319476)
32. Mooney DJ, Mikos AG. The promise of tissue engineering: Growing new organs. Sci Am. 1999;280:38-43.